Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
Incretin Axis in Type 1 Diabetes Mellitus
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 20
- Registration Number
- NCT02725502
- Locations
- 🇮🇳
Department of Endocrinology, PGIMER, Chandigarh, India
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
- Conditions
- Type 2 DiabetesChronic Kidney Diseases
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT02608177
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Linagliptin's Effect on CD34+ Stem Cells
- Conditions
- Type 2 DiabetesImpaired Renal Function
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 31
- Registration Number
- NCT02467478
- Locations
- 🇺🇸
The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 275
- Registration Number
- NCT02453555
- Locations
- 🇯🇵
Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵Nakakinen Clinic, Ibaraki, Naka, Japan
🇯🇵Hiraoka Naika Clinic, Hiroshima, I.M., Hiroshima, Hiroshima, Japan
Linagliptin and Mesenchymal Stem Cells: A Pilot Study
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- University of Nevada, Reno
- Target Recruit Count
- 10
- Registration Number
- NCT02442817
- Locations
- 🇺🇸
University of Nevada School of Medicine, Reno, Nevada, United States
A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02429232
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 89
- Registration Number
- NCT02401880
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Germany
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
- Conditions
- Arterial HypertensionAlbuminuria
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT02376075
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rhineland-Palatinate, Germany
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 40
- Registration Number
- NCT02372630
- Locations
- 🇺🇸
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
Effects of Linagliptin on Endothelial Function
- Conditions
- Type 2 DiabetesCoronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 49
- Registration Number
- NCT02350478
- Locations
- 🇦🇹
Medical University of Graz, Department for Internal Medicine, Graz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.